Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Menarini
Biotech
Insilico nabs $500M+ biobucks deal for preclinical cancer asset
Menarini's Stemline Therapeutics is paying $12 million upfront for licensing rights to Insilico Medicine’s preclinical cancer candidate.
Gabrielle Masson
Jan 4, 2024 10:00am
Context cuts excess fat to carry biotech into ‘24
Sep 28, 2022 11:00am
As Sanofi's SERD falls, Menarini's advances with EU review
Aug 19, 2022 9:20am
Menarini, chased by 3 Big Pharmas, records breast cancer win
Oct 21, 2021 7:05am
Debiopharm buys ImmunoGen ADC to grow cancer pipeline
May 24, 2017 4:26am
Chugai licenses out early-stage cancer candidate to Menarini
Nov 28, 2016 3:54am
